Drug intelligence / Profile preview

Erbrex

Development stage: Unknown
Lead developer: Homviora Arzneimittel Dr. Hagedorn
Administration: Oral

Overview

**Erbrex** is a nonprescription German homeopathic fixed-dose tablet developed and marketed by Homviora for vomiting of various causes. Each tablet contains the homeopathic triturations Apomorphinum hydrochloricum Trit. D3 and Cocculus Trit. D3; the product is also promoted for nausea and travel sickness. Its labeled indication is derived from homeopathic medicinal-use profiles rather than a defined target-based pharmacological mechanism. ([homviora.de](https://www.homviora.de/arzneimittel/erbrex-beipackzettel))

Brand names: Erbrex

Beyond the preview

Go deeper on Erbrex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erbrex.

Explore the full profile